Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Verzenios Summary of Product Characteristics (SmPC)

Verzenios® ▼ (abemaciclib): Visual Toxicity

Visual toxicities were observed with use of abemaciclib in the MONARCH clinical trials.

Incidence of Visual Toxicities

The most common abemaciclib visual toxicities in MONARCH 2, and MONARCH 3 are presented in Table 1

Table 1. All Grade Visual Toxicities in the Abemaciclib Arms of the MONARCH Clinical Trials1

Event, n (%)

MONARCH 2

N=441

MONARCH 3

N=327

Diplopia

1 (0.2)

1 (0.3)

Visual Acuity Reduced

1 (0.2)

1 (0.3)

Vision Blurred

12 (2.7)

6 (1.8)

In the abemaciclib plus fulvestrant arm of MONARCH 2, photopsia was experienced in 2 patients (0.5%) and scintillating scotoma was experienced in 1 patient (0.2%).1

Grade 3 unilateral blindness was experienced by 1 patient (0.3%) in the abemaciclib plus nonsteroidal aromatase inhibitor arm of MONARCH 3. Aside from the patient who experienced unilateral blindness in MONARCH 3, all other visual toxicities experienced by patients in MONARCH 2, and MONARCH 3 were of grade 1 or grade 2 severity.1

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: August 19, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question